Profile
AKAN ZTS TAK HLN TEVA NBIX
Company Name Akanda Corp. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $2.15M $52.30B $45.13B $43.16B $34.51B $15.32B
Employees 0.05K 13.80K 49.28K 24.56K 37.00K 1.80K
CEO Katharyn Field Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Kyle W. Gano
Ratings
AKAN ZTS TAK HLN TEVA NBIX
Quant Rating Score 3 4 3 3 3 3
Quant Rating Neutral Buy Neutral Neutral Neutral Neutral
Trading
AKAN ZTS TAK HLN TEVA NBIX
Last Close $1.04 $118.8 $14.14 $9.68 $24.59 $143.56
High 52 $4.77 $178.71 $15.52 $11.41 $25.83 $154.8
Low 52 $1.05 $118.8 $12.89 $8.73 $12.82 $87.59
Price vs. 52 Week High -78.2 % -33.52 % -8.89 % -15.16 % -4.8 % -7.26 %
Price vs. 52 Week Low -0.95 % 0 % 9.7 % 10.88 % 91.81 % 63.9 %
Total Return
AKAN ZTS TAK HLN TEVA NBIX
1 Month Return -54.59 % -17.53 % 0.71 % 2.11 % 27.34 % 2.48 %
3 Month Return -22.39 % -21.96 % -6.73 % -0.05 % 36.16 % 7.83 %
6 Month Return -13.33 % -27.13 % 0.21 % -10.37 % 45.16 % 18.63 %
9 Month Return -40.57 % -24.08 % 1.73 % -3.1 % 48.4 % 25.96 %
YTD Return -35 % -27.09 % 6.8 % 1.47 % 11.57 % 5.17 %
1 Year Return -25.71 % -32.33 % 3.82 % 2.11 % 46.28 % 20.51 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AKAN ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.69 % 4.41 % 1.56 % - -
Dividend Paid and Capex Coverage Ration (TTM) -1.9 % 1.89 % 2.01 % 2.01 % 2.78 % 14.57 %
Dividend Per Share (TTM) - 2 % 198 % 0.06 % - -
Payout Ratio (TTM) - 32.55 % 226.17 % 27.27 % - -
Profitability
AKAN ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 24.91 % 70.63 % 52.77 % 61.81 % 49.6 % 98.37 %
Return on Assets TTM -51.76 % 17.49 % 0.98 % 4.78 % -0.39 % 10.03 %
Return on Equity TTM -92.6 % 53.56 % 1.95 % 9.4 % -2.58 % 15.82 %
Return on Capital Employed TTM -102.48 % 26.48 % 4.8 % 8.34 % 3.16 % 15.17 %
Net Income Per EBT TTM 125.32 % 79.59 % 72.4 % 76.52 % 222.54 % 68.09 %
EBT Per Ebit TTM 74.58 % 94.2 % 33.29 % 88.09 % -7.94 % 114.25 %
EBIT Per Revenue TTM -523.8 % 37.63 % 12.68 % 20.49 % 5.38 % 20.51 %
Cash Flow To Debt Ratio TTM -1128.18 % 1429.41 % 22.35 % 12.02 % 7.93 % 148.65 %
Receivables Turnover TTM 1.02 6.1 6.59 5.14 4.67 3.69
Payables Turnover TTM 0.21 6.73 5.02 1.18 3.35 0.37
Inventory Turnover TTM - 1.12 1.71 3.72 2.4 0.63
Fixed Asset Turnover TTM 35.77 % 241.44 % 229.02 % 589.57 % 321.73 % 473.81 %
Asset Turnover TTM 10.57 % 61.99 % 31.99 % 34.62 % 41.43 % 62.89 %
Operating Cash Flow Per Share TTM -3.82 6.58 643.53 0.11 1.21 6.41
Free Cash Flow Per Share TTM -5.83 5.06 521.29 0.1 0.78 5.97
Cash Per Share TTM 368.39 % 470.54 % 22368.59 % 7.46 % 188.4 % 1121.53 %
Operating Cash Flow Sales Ratio TTM -475.74 % 31.03 % 22.48 % 9.32 % 8.36 % 23.74 %
Free Cash Flow Operating Cash Flow Ratio TTM 152.71 % 76.82 % 81.01 % 90.65 % 64.03 % 93.14 %
Cash Flow Coverage Ratios TTM -1128.18 % 1429.41 % 22.35 % 12.02 % 7.93 % 148.65 %
Price To Free Cash Flows Ratio TTM -0.35 23.35 8.68 34.34 38.64 25.82
Price To Operating Cash Flows Ratio TTM -0.25 18.02 6.98 31.66 24.73 24.04
Price Cash Flow Ratio TTM -0.25 18.02 6.98 31.66 24.73 24.04
Income Statement (TTM)
AKAN ZTS TAK HLN TEVA NBIX
Revenue $0B $9.26B $4581.55B $11.23B $16.54B $2.36B
Gross Profit $0B $6.4B $3001.33B $6.95B $8.06B $2.32B
Gross Profit Ratio 24.91% 69.1% 65.51% 61.85% 48.74% 98.56%
EBITDA $-0B $3.87B $1210.51B $2.51B $4.43B $0.64B
Net Income $-0B $2.49B $107.93B $1.44B $-1.64B $0.34B
EPS Diluted -3.93 5.47 33.62 0.32 -1.45 3.29
Balance Sheet (MRQ)
AKAN ZTS TAK HLN TEVA NBIX
Long Term Debt $0B $5.39B $3966.33B $8.62B $16.3B $0.46B
Total Liabilities $0B $9.47B $7312.37B $18.09B $33.61B $1.13B
Total Equity $0B $4.77B $6935.98B $16.22B $5.72B $2.59B
Total Investments $0B $0.03B $382.4B $0.14B $0B $1.71B
Total Debt $0B $6.74B $4515.27B $10.1B $18.08B $0.46B
Total Assets $0.01B $14.24B $14248.34B $34.32B $39.33B $3.72B
Cash Flow Statement (TTM)
AKAN ZTS TAK HLN TEVA NBIX
Net Income $-0B $2.5B $107.93B $1.44B $-1.65B $0.34B
Inventory $0B $-0.04B $-34.97B $0.22B $0B $-0.02B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $0B
Operating Cash Flow $-0B $2.95B $1057.18B $2.3B $2.55B $0.6B
Capital Expenditure $-0B $-0.66B $-200.8B $-0.25B $-0.5B $-0.04B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 5.42
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 4.955
ALVOW Alvotech 0.9077
AMPH Amphastar Pharmaceuticals, Inc. 25.51
AMRX Amneal Pharmaceuticals, Inc. 12.225
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 81.65
APUS Apimeds Pharmaceuticals US, Inc 2.13
AQST Aquestive Therapeutics, Inc. 5.74
ASRT Assertio Holdings, Inc. 0.729
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 21.375
AYTU Aytu BioPharma, Inc. 2.3826
ETFs With Exposure to AKAN
Ticker ETF Name Weight Percentage Price
MJ ETFMG Alternative Harvest ETF 0 38.5001
Unlock